Future SUPAC Guidances Will Be "Dosage-Independent" - FDA's Sager
This article was originally published in The Tan Sheet
Executive Summary
Future guidances following the Scale-Up & Post-Approval Changes model likely will not focus on individual dosage forms, FDA Office of Pharmaceutical Science Quality Implementation Associate Director Nancy Sager told the American Association of Pharmaceutical Science March 16 in Crystal City, Va.